Abstract
A major challenge in photodynamic cancer therapy (PDT) is avoiding PDT-induced hypoxia, which can lead to cancer recurrence and progression through activation of various angiogenic factors and significantly reduce treatment outcomes. Reported here is an acetazolamide (AZ)-conjugated BODIPY photosensitizer (AZ-BPS) designed to mitigate the effects of PDT-based hypoxia by combining the benefits of anti-angiogenesis therapy with PDT. AZ-BPS showed specific affinity to aggressive cancer cells (MDA-MB-231 cells) that overexpress carbonic anhydrase IX (CAIX). It displayed enhanced photocytotoxicity compared to a reference compound, BPS, which is an analogous PDT agent that lacks an acetazolamide unit. AZ-BPS also displayed an enhanced in vivo efficacy in a xenograft mouse tumor regrowth model relative to BPS, an effect attributed to inhibition of tumor angiogenesis by both PDT-induced ROS generation and CAIX knockdown. AZ-BPS was evaluated successfully in clinical samples collected from breast cancer patients. We thus believe that the combined approach described here represents an attractive therapeutic approach to targeting CAIX-overexpressing tumors.
| Original language | English |
|---|---|
| Pages (from-to) | 7595-7602 |
| Number of pages | 8 |
| Journal | Journal of the American Chemical Society |
| Volume | 139 |
| Issue number | 22 |
| DOIs | |
| Publication status | Published - 2017 Jun 7 |
Fingerprint
ASJC Scopus subject areas
- Catalysis
- Chemistry(all)
- Biochemistry
- Colloid and Surface Chemistry
Cite this
Overcoming the Limits of Hypoxia in Photodynamic Therapy : A Carbonic Anhydrase IX-Targeted Approach. / Jung, Hyo Sung; Han, Jiyou; Shi, Hu; Koo, Seyoung; Singh, Hardev; Kim, Hyo Jin; Sessler, Jonathan L.; Lee, Jin Yong; Kim, Jong-Hoon; Kim, Jong Seung.
In: Journal of the American Chemical Society, Vol. 139, No. 22, 07.06.2017, p. 7595-7602.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Overcoming the Limits of Hypoxia in Photodynamic Therapy
T2 - A Carbonic Anhydrase IX-Targeted Approach
AU - Jung, Hyo Sung
AU - Han, Jiyou
AU - Shi, Hu
AU - Koo, Seyoung
AU - Singh, Hardev
AU - Kim, Hyo Jin
AU - Sessler, Jonathan L.
AU - Lee, Jin Yong
AU - Kim, Jong-Hoon
AU - Kim, Jong Seung
PY - 2017/6/7
Y1 - 2017/6/7
N2 - A major challenge in photodynamic cancer therapy (PDT) is avoiding PDT-induced hypoxia, which can lead to cancer recurrence and progression through activation of various angiogenic factors and significantly reduce treatment outcomes. Reported here is an acetazolamide (AZ)-conjugated BODIPY photosensitizer (AZ-BPS) designed to mitigate the effects of PDT-based hypoxia by combining the benefits of anti-angiogenesis therapy with PDT. AZ-BPS showed specific affinity to aggressive cancer cells (MDA-MB-231 cells) that overexpress carbonic anhydrase IX (CAIX). It displayed enhanced photocytotoxicity compared to a reference compound, BPS, which is an analogous PDT agent that lacks an acetazolamide unit. AZ-BPS also displayed an enhanced in vivo efficacy in a xenograft mouse tumor regrowth model relative to BPS, an effect attributed to inhibition of tumor angiogenesis by both PDT-induced ROS generation and CAIX knockdown. AZ-BPS was evaluated successfully in clinical samples collected from breast cancer patients. We thus believe that the combined approach described here represents an attractive therapeutic approach to targeting CAIX-overexpressing tumors.
AB - A major challenge in photodynamic cancer therapy (PDT) is avoiding PDT-induced hypoxia, which can lead to cancer recurrence and progression through activation of various angiogenic factors and significantly reduce treatment outcomes. Reported here is an acetazolamide (AZ)-conjugated BODIPY photosensitizer (AZ-BPS) designed to mitigate the effects of PDT-based hypoxia by combining the benefits of anti-angiogenesis therapy with PDT. AZ-BPS showed specific affinity to aggressive cancer cells (MDA-MB-231 cells) that overexpress carbonic anhydrase IX (CAIX). It displayed enhanced photocytotoxicity compared to a reference compound, BPS, which is an analogous PDT agent that lacks an acetazolamide unit. AZ-BPS also displayed an enhanced in vivo efficacy in a xenograft mouse tumor regrowth model relative to BPS, an effect attributed to inhibition of tumor angiogenesis by both PDT-induced ROS generation and CAIX knockdown. AZ-BPS was evaluated successfully in clinical samples collected from breast cancer patients. We thus believe that the combined approach described here represents an attractive therapeutic approach to targeting CAIX-overexpressing tumors.
UR - http://www.scopus.com/inward/record.url?scp=85020382009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020382009&partnerID=8YFLogxK
U2 - 10.1021/jacs.7b02396
DO - 10.1021/jacs.7b02396
M3 - Article
C2 - 28459562
AN - SCOPUS:85020382009
VL - 139
SP - 7595
EP - 7602
JO - Journal of the American Chemical Society
JF - Journal of the American Chemical Society
SN - 0002-7863
IS - 22
ER -